Effectiveness of deferiprone in transfusion‐independent beta‐thalassemia/HbE patients

References

• Viprakasit V, Lee‐Lee C, Chong QT, Lin KH, Khuhapinant A. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009;90:435–45.
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Ketvichit P, Pootrakul P, Siritanaratkul N, Piankijagum A, Wasi P. Clinical manifestation of beta‐thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 2000;22:552–7.
   PubMed Web of Science ®Google Scholar
• Nuntakarn L, Fucharoen S, Fucharoen G, Sanchaisuriya K, Jetsrisuparb A, Wiangnon S. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E‐beta‐thalassemia in Northeast Thailand. Blood Cells Mol Dis 2009;42:32–5.
   PubMed Web of Science ®Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107:3436–41.
   PubMed Web of Science ®Google Scholar
• Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol 2009;147:634–40.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al.. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97:3411–6.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Pattoneri P. Oral iron chelators. Annu Rev Med 2009;60:25–38.
   PubMed Web of Science ®Google Scholar
• Cianciulli P. Treatment of iron overload in thalassemia. Pediatr Endocrinol Rev 2008;6(Suppl 1):208–13.
   PubMedGoogle Scholar
• Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al.. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review. Transfusion 2007;47:1919–29.
   PubMed Web of Science ®Google Scholar
• Taher A, Chamoun FM, Koussa S, Saad MA, Khoriaty AI, Neeman R, et al.. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173–7.
   PubMed Web of Science ®Google Scholar
• Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin 2008;32:49–62.
   PubMed Web of Science ®Google Scholar
• Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta‐thalassemia major patients. Hemoglobin 2006;30:229–38.
   PubMed Web of Science ®Google Scholar
• Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion‐dependent thalassaemia: a systematic review and meta‐analysis. Br J Haematol 2008;141:882–90.
   PubMed Web of Science ®Google Scholar
• Vlachaki E, Tselios K, Perifanis V, Tsatra I, Tsayas I. Deferiprone‐related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature. Clin Rheumatol 2008;27:1459–61.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL. Oral iron chelators. Pediatr Clin North Am 2008;55:461–482, x.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553–84.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008;32:1–15.
   PubMed Web of Science ®Google Scholar
• Cario H, Janka‐Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E. Recent developments in iron chelation therapy. Klin Padiatr 2007;219:158–65.
   PubMed Web of Science ®Google Scholar
• Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann NY Acad Sci 2005;1054:175–82.
   PubMed Web of Science ®Google Scholar
• Victor Hoffbrand A. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005;18:299–317.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al.. Iron‐chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332:918–22.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al.. Long‐term safety and effectiveness of iron‐chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417–23.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, AL‐Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long‐term trial of deferiprone in 51 transfusion‐dependent iron overloaded patients. Blood 1998;91:295–300.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, et al.. Clinical trial of deferiprone iron chelation therapy in beta‐thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305–10.
   PubMed Web of Science ®Google Scholar
• Davis BA, O’Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004;104:263–9.
   PubMed Web of Science ®Google Scholar
• Arques S, Roux E, Luccioni R. Current clinical applications of spectral tissue Doppler echocardiography (E/E′ ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function. Cardiovasc Ultrasound 2007;5:16.
   PubMedGoogle Scholar
• Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, et al.. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523–30.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007;92:658–65.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al.. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250–94.
   PubMed Web of Science ®Google Scholar
• Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta 2010;1800:760–9.
   PubMed Web of Science ®Google Scholar
• Taher A, El Rassi F, Isma’eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008;93:1584–6.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al.. Survival in medically treated patients with homozygous beta‐thalassemia. N Engl J Med 1994;331:574–8.
   PubMed Web of Science ®Google Scholar
• Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, et al.. Levels of non‐transferrin‐bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009;146:569–72.
   PubMed Web of Science ®Google Scholar
• Domenica Cappellini M, Tavazzi D, Duca L, Marelli S, Fiorelli G. Non‐transferrin‐bound iron, iron‐related oxidative stress and lipid peroxidation in beta‐thalassemia intermedia. Transfus Sci 2000;23:245–6.
   PubMedGoogle Scholar
• Al‐Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non‐transferrin‐bound iron in beta‐thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol 1992;82:431–6.
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI‐labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277–87.
   PubMed Web of Science ®Google Scholar
• Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, et al.. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009;84:29–33.
   PubMed Web of Science ®Google Scholar
• Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum nontransferrin‐bound iron in chelation therapy and iron supplementation. Blood 2000;95:2975–82.
   PubMed Web of Science ®Google Scholar
• Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670–7.
   PubMed Web of Science ®Google Scholar
• Hill GE, Miller JA, Baxter BT, Klassen LW, Duryee MJ, Tuma DJ, et al.. Association of malondialdehyde‐acetaldehyde (MAA) adducted proteins with atherosclerotic‐induced vascular inflammatory injury. Atherosclerosis 1998;141:107–16.
   PubMed Web of Science ®Google Scholar
• Chuang CH, Huang CE, Chen HL. DNA strand breakage and lipid peroxidation after exposure to welding fumes in vivo. Mutagenesis 2010;25:71–6.
   PubMed Web of Science ®Google Scholar
• Willis MS, Klassen LW, Tuma DJ, Thiele GM. Malondialdehyde‐acetaldehyde‐haptenated protein induces cell death by induction of necrosis and apoptosis in immune cells. Int Immunopharmacol 2002;2:519–35.
   PubMed Web of Science ®Google Scholar
• Linpisarn S, Satoh K, Mikami T, Orimo H, Shinjo S, Yoshino Y. Effects of iron on lipid peroxidation. Int J Hematol 1991;54:181–8.
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta‐thalassemia. Curr Opin Hematol 2000;7:106–12.
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al.. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096–101.
   PubMed Web of Science ®Google Scholar
• Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008;8:620–32.
   PubMed Web of Science ®Google Scholar
• Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsante E, et al.. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart 2003;89:762–6.
   PubMed Web of Science ®Google Scholar
• Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990;82:88–94.
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta‐thalassemia major. Circulation 1993;88:1127–35.
   PubMed Web of Science ®Google Scholar
• Isma’eel H, Chafic AH, Rassi FE, Inati A, Koussa S, Daher R, et al.. Relation between iron‐overload indices, cardiac echo‐Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol 2008;102:363–7.
   PubMed Web of Science ®Google Scholar
• Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ, Griffith P, et al. Detection of early cardiac dysfunction in patients with severe beta‐thalassemia and chronic iron overload. N Engl J Med 1979;301:1143–8.
   PubMed Web of Science ®Google Scholar
• Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971;51:209–21.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D. Pulmonary hypertension in beta‐thalassemia. Ann NY Acad Sci 2005;1054:342–9.
   PubMed Web of Science ®Google Scholar
• Grubina R, Huang Z, Shiva S, Joshi MS, Azarov I, Basu S, et al.. Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy‐ and oxyhemoglobin. J Biol Chem 2007;282:12916–27.
   PubMed Web of Science ®Google Scholar
• Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis‐associated pulmonary hypertension, and nitric oxide scavenging by cell‐free hemoglobin. Blood 2007;110:2166–72.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed) 2009;1:161–78.
   PubMedGoogle Scholar